Abstract 785
Background
Immune checkpoint inhibitors targeting PD-1/PD-L1 axis have shown promising results in patients with non-small-cell lung cancer (NSCLC); however, the objective response rate is less than 30%. One major PD-L1 inducer, interferon γ (IFNg), has anti-tumour properties and is secreted by T cells and NK cells. IFNg-induced PD-L1 is considered to be a major mechanism that facilitates cancer cell escape from host immunity. Therefore, a better understanding of how IFNg stimulus influences the regulation of PD-L1 expression in cancer cells is warranted.
Methods
NSCLC cell lines: A549, PC-9, and LC2/ad were used for in vitro assays. Comparative analysis between IFNg and EGF was conducted in LC2/ad cells because EGF stimuli also enhanced PD-L1 expression in this cell line. PD-L1 expression was evaluated using flow cytometry while cell signalling pathway analysis was assessed using phospho-receptor tyrosine kinase arrays. To assess the NK cell-mediated cytotoxicity, NK cells were collected from healthy donors. NK killing was evaluated by lactate dehydrogenase release assay. Apoptotic cells were assessed via flow cytometry using Annexin V.
Results
IFNg stimulus significantly upregulated PD-L1 expression in all cell lines. In LC2/ad cells, IFNg activated STAT1 signalling while EGF activated AKT, MAPK, and ribosomal protein S6 (RPS6). Although IFNg-induced PD-L1 was clearly blocked by the JAK-STAT inhibitor, tofacitinib, EGF-induced PD-L1 was not. Both IFNg- and EGF-induced PD-L1 were blocked by PI3K and MAPK inhibitors; however, they were not blocked by the RPS6 inhibitor. Interestingly, IFNg downregulated NK cell-activating ligand expression while upregulating MHC class I molecules, the phenotype of which can theoretically escape NK cells easily. Thus, we confirmed that IFNg stimulus attenuated NK cell-mediated cytotoxicity in LC2/ad cells; however, tofacitinib blocked IFNg-reduced NK killing. We also confirmed that tofacitinib, at concentrations less than 3 μM, did not cause NK cell apoptosis.
Conclusions
Tofacitinib blocks IFNg-induced immunoescape from NK cells in NSCLC cells, thereby suggesting that NK cell therapy combined with tofacitinib might be a promising strategy in overcoming tumour immune escape.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Riki Okita.
Funding
Japan Society for the Promotion of Science (JSPS) Kakenhi Grant (25462189 and 16K10696),.
Disclosure
M. Nakata: Research grant / Funding (institution), The sponsor had no control over the interpretation or presentation of this work.: Kyowa Kirin. All other authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract